Self-Driving CAR: The Promise of In Vivo CAR-T Therapy for Hematologic Malignancies 

In Vivo CAR-T therapies represent a paradigm shift in immuno-oncology, offering a promising approach toward scalable, accessible, cost-effective treatment for hematologic malignancies. In Vivo CAR-T platforms eliminate the need for complex cell harvesting and manufacturing, potentially broadening patient access and reducing logistical burdens. As these therapies advance, their transformative potential in hematologic malignancies becomes increasingly evident, with early data suggesting robust efficacy and safety.